Skip to main content
NASDAQ:PRLD

Prelude Therapeutics News Headlines

$39.15
-5.15 (-11.63 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$38.02
$44.94
50-Day Range
$31.48
$49.44
52-Week Range
$23.69
$95.38
Volume336,228 shs
Average Volume223,629 shs
Market Capitalization$1.39 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Prelude Therapeutics (NASDAQ PRLD) News Headlines Today

SourceHeadline
Zacks Investment Research Upgrades Prelude Therapeutics (NASDAQ:PRLD) to BuyZacks Investment Research Upgrades Prelude Therapeutics (NASDAQ:PRLD) to Buy
marketbeat.com - May 4 at 6:57 AM
Prelude Therapeutics (NASDAQ:PRLD) Upgraded at Zacks Investment ResearchPrelude Therapeutics (NASDAQ:PRLD) Upgraded at Zacks Investment Research
marketbeat.com - April 27 at 5:15 AM
Prelude Therapeutics (NASDAQ:PRLD) Trading Down 8%Prelude Therapeutics (NASDAQ:PRLD) Trading Down 8%
americanbankingnews.com - May 13 at 1:39 PM
Are Insiders Buying Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock?Are Insiders Buying Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock?
finance.yahoo.com - May 13 at 12:40 PM
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 6.1%Prelude Therapeutics (NASDAQ:PRLD) Stock Price Up 6.1%
americanbankingnews.com - May 12 at 1:38 PM
Prelude Therapeutics (NASDAQ:PRLD) Releases Quarterly  Earnings Results, Misses Estimates By $0.05 EPSPrelude Therapeutics (NASDAQ:PRLD) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS
americanbankingnews.com - May 12 at 12:40 PM
Insider Selling: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Sells 10,000 Shares of StockInsider Selling: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Sells 10,000 Shares of Stock
americanbankingnews.com - May 11 at 8:46 PM
Prelude Therapeutics (NASDAQ:PRLD) Sees Strong Trading VolumePrelude Therapeutics (NASDAQ:PRLD) Sees Strong Trading Volume
americanbankingnews.com - May 11 at 10:56 AM
Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations UpdatePrelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update
finance.yahoo.com - May 11 at 8:26 AM
Insider Selling: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Sells 15,000 Shares of StockInsider Selling: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Sells 15,000 Shares of Stock
americanbankingnews.com - May 10 at 5:56 PM
Prelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care ConferencePrelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care Conference
finance.yahoo.com - May 5 at 10:59 AM
Prelude Therapeutics (NASDAQ:PRLD) Shares Gap Down  After Insider SellingPrelude Therapeutics (NASDAQ:PRLD) Shares Gap Down After Insider Selling
americanbankingnews.com - May 3 at 11:06 AM
-$0.41 EPS Expected for Prelude Therapeutics Incorporated (NASDAQ:PRLD) This Quarter-$0.41 EPS Expected for Prelude Therapeutics Incorporated (NASDAQ:PRLD) This Quarter
americanbankingnews.com - May 3 at 9:50 AM
Prelude Therapeutics (NASDAQ:PRLD) Coverage Initiated by Analysts at HC WainwrightPrelude Therapeutics (NASDAQ:PRLD) Coverage Initiated by Analysts at HC Wainwright
americanbankingnews.com - May 3 at 8:34 AM
Prelude Therapeutics (NASDAQ:PRLD) Earns Buy Rating from Analysts at HC WainwrightPrelude Therapeutics (NASDAQ:PRLD) Earns Buy Rating from Analysts at HC Wainwright
americanbankingnews.com - May 3 at 8:34 AM
Prelude Therapeutics (NASDAQ:PRLD) Stock Price Down 4.4%Prelude Therapeutics (NASDAQ:PRLD) Stock Price Down 4.4%
americanbankingnews.com - April 27 at 12:54 PM
HC Wainwright Initiates Coverage on Prelude Therapeutics (NASDAQ:PRLD)HC Wainwright Initiates Coverage on Prelude Therapeutics (NASDAQ:PRLD)
americanbankingnews.com - April 26 at 7:56 AM
Insider Selling: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Sells 25,000 Shares of StockInsider Selling: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Sells 25,000 Shares of Stock
americanbankingnews.com - April 21 at 10:44 PM
Prelude Therapeutics (NASDAQ:PRLD)  Shares Down 5.7% Prelude Therapeutics (NASDAQ:PRLD) Shares Down 5.7%
americanbankingnews.com - April 21 at 11:43 AM
Prelude Therapeutics (NASDAQ:PRLD) Shares Up 3.2%Prelude Therapeutics (NASDAQ:PRLD) Shares Up 3.2%
americanbankingnews.com - April 20 at 1:40 PM
Prelude Therapeutics (PRLD) Enters Oversold TerritoryPrelude Therapeutics (PRLD) Enters Oversold Territory
finance.yahoo.com - April 20 at 12:58 PM
Oversold Conditions For Prelude Therapeutics (PRLD)Oversold Conditions For Prelude Therapeutics (PRLD)
nasdaq.com - April 16 at 6:37 PM
Prelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational UpdatePrelude Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Update
finance.yahoo.com - March 16 at 12:45 PM
Prelude Therapeutics Becomes Oversold (PRLD)Prelude Therapeutics Becomes Oversold (PRLD)
nasdaq.com - March 5 at 3:24 PM
Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters Option to Purchase Additional SharesPrelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
marketwatch.com - January 12 at 4:34 AM
Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesPrelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - January 11 at 6:32 PM
Prelude, Onconova plan multimillion-dollar stock salesPrelude, Onconova plan multimillion-dollar stock sales
bizjournals.com - January 11 at 1:28 PM
Prelude Therapeutics Announces Pricing of Upsized Public OfferingPrelude Therapeutics Announces Pricing of Upsized Public Offering
finance.yahoo.com - January 7 at 3:45 AM
Prelude Therapeutics Announces Launch of Proposed Public OfferingPrelude Therapeutics Announces Launch of Proposed Public Offering
finance.yahoo.com - January 4 at 5:50 PM
Prelude Therapeutics, Inc. (PRLD)Prelude Therapeutics, Inc. (PRLD)
realmoney.thestreet.com - December 31 at 12:50 AM
Heres Why Were Not At All Concerned With Prelude Therapeutics (NASDAQ:PRLD) Cash Burn SituationHere's Why We're Not At All Concerned With Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation
finance.yahoo.com - December 25 at 10:53 AM
Is PRLD A Good Stock To Buy Now?Is PRLD A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 6:40 AM
Prelude Therapeutics Announces Third Quarter 2020 Financial ResultsPrelude Therapeutics Announces Third Quarter 2020 Financial Results
finance.yahoo.com - November 10 at 7:53 AM
Prelude Therapeutics Inc.Prelude Therapeutics Inc.
barrons.com - November 6 at 6:31 PM
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.